295 related articles for article (PubMed ID: 35709811)
21. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
23. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
[TBL] [Abstract][Full Text] [Related]
24. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
Porras C; Sampson JN; Herrero R; Gail MH; Cortés B; Hildesheim A; Cyr J; Romero B; Schiller JT; Montero C; Pinto LA; Schussler J; Coronado K; Sierra MS; Kim JJ; Torres CM; Carvajal L; Wagner S; Campos NG; Ocampo R; Kemp TJ; Zuniga M; Lowy DR; Avila C; Chanock S; Castrillo A; Estrada Y; Barrientos G; Monge C; Oconitrillo MY; Kreimer AR
Vaccine; 2022 Jan; 40(1):76-88. PubMed ID: 34857420
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.
Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F
Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783
[TBL] [Abstract][Full Text] [Related]
27. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
[TBL] [Abstract][Full Text] [Related]
28. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
29. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
30. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D;
Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial.
Sierra MS; Tsang SH; Hu S; Porras C; Herrero R; Kreimer AR; Schussler J; Boland J; Wagner S; Cortes B; Rodríguez AC; Quint W; van Doorn LJ; Schiffman M; Sampson JN; Hildesheim A;
J Infect Dis; 2021 Aug; 224(3):503-516. PubMed ID: 33326576
[TBL] [Abstract][Full Text] [Related]
34. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.
Kechagias KS; Kalliala I; Bowden SJ; Athanasiou A; Paraskevaidi M; Paraskevaidis E; Dillner J; Nieminen P; Strander B; Sasieni P; Veroniki AA; Kyrgiou M
BMJ; 2022 Aug; 378():e070135. PubMed ID: 35922074
[TBL] [Abstract][Full Text] [Related]
35. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial.
Panagiotou OA; Befano BL; Gonzalez P; Rodríguez AC; Herrero R; Schiller JT; Kreimer AR; Schiffman M; Hildesheim A; Wilcox AJ; Wacholder S;
BMJ; 2015 Sep; 351():h4358. PubMed ID: 26346155
[TBL] [Abstract][Full Text] [Related]
36. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.
Powell SE; Hariri S; Steinau M; Bauer HM; Bennett NM; Bloch KC; Niccolai LM; Schafer S; Unger ER; Markowitz LE
Vaccine; 2012 Dec; 31(1):109-13. PubMed ID: 23137842
[TBL] [Abstract][Full Text] [Related]
37. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
[TBL] [Abstract][Full Text] [Related]
38. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
39. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
Verdoodt F; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
[TBL] [Abstract][Full Text] [Related]
40. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]